Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,240
Total Claims
$1.8M
Drug Cost
468
Beneficiaries
$3,833
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+172%
Cost per patient vs peers
$3,833 vs $1,411 avg
+63%
Brand preference vs peers
17.3% vs 10.6% avg
Brand vs Generic
Brand: 1,699 claims · $1.6M
Generic: 8,096 claims · $167K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 294 | $417K |
| Sitagliptin Phos/Metformin Hcl | 103 | $113K |
| Apixaban | 86 | $109K |
| Tenofovir Alafenamide | 60 | $105K |
| Icosapent Ethyl | 181 | $100K |
| Rivaroxaban | 66 | $71K |
| Liraglutide | 40 | $66K |
| Semaglutide | 32 | $51K |
| Insulin Aspart | 28 | $45K |
| Insulin Glargine,hum.Rec.Anlog | 76 | $44K |
| Dulaglutide | 24 | $40K |
| Empagliflozin/Metformin Hcl | 25 | $34K |
| Budesonide/Formoterol Fumarate | 67 | $34K |
| Linagliptin | 23 | $33K |
| Sitagliptin Phosphate | 22 | $32K |
Prescribing Profile
Patient Profile
74
Avg Age
49%
Female
1.10
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data